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ABSTRACT 
Purpose: With the description of circulating fetal DNA in maternal blood, non-invasive prenatal 
diagnostics became theoretically possible. As the presence of background maternal DNA 
interferes with the detection of fetal DNA, analytical methods require genetic markers capable of 
distinguishing by quantitative or targeted approaches the minor population of DNA molecules of 
the fetus. Here we evaluate the feasibility of analyzing fetal DNA with novel DIP-STR genetic 
markers, designed for the investigation of forensic mixed biological evidence. 
Methods: The DIP-STR molecular approach is based on sequence-specific analysis of paternally 
inherited fetal alleles. These sequences are biallelic deletion/insertion polymorphisms (DIP) 
located very close to STR markers, for combined analysis. In this study, 48 women were tested 
with 28 DIP-STRs during the first, second and third trimester of pregnancy. 
Results: Positive results were obtained across markers, including longer ones (386 base-pairs) 
and with blood samples collected during early pregnancy, such as ten weeks of gestational age.  
Conclusions: These data show that DIP-STR markers can be used to amplify specific genomic 
regions of circulating fetal DNA to obtain targeted genetic information. This method may 
contribute to developments in non-invasive prenatal paternity testing and diagnosis of certain 
genetic diseases. 
 
Key Words noninvasive prenatal testing; paternity testing; cell-free DNA; DIP-STR; DNA 
mixture   
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INTRODUCTION 
In obstetric care, prenatal screening and diagnosis allows women to make informed choices 
about the continuation of the pregnancy affected by genetic conditions such as: sex-linked 
disorders,1 fetal RhD status,2,3 β-thalassemia,4-6 congenital adrenal hyperplasia,7 chromosomal 
aneuploidy,8,9 pre-eclampsia10,11 and others.12 In forensic science, prenatal paternity testing aims 
at helping those pregnant women who have been victims of sexual assault and are unclear about 
the paternity of their unborn child. 
Unfortunately, many definitive prenatal diagnoses of diseases including reliable prenatal 
paternity tests require the analysis of fetal genetic material, obtained through procedures 
performed at advanced gestational age (about 15 weeks) and that are associated to a certain 
degree of harm to the mother and the fetus. For instance, amniocentesis carries a miscarriage risk 
of 1 in 300 to 1 in 50013 and a small risk of other complications,14,15 direct chorionic villus 
sampling carries a similar miscarriage risk in addition to a 1 in 3000 risk of fetal limb reduction 
defects, especially when performed before the 10th week of gestation.16,17 
New possibilities of developing prenatal diagnostic methods that are noninvasive, emerged with 
the discovery of the presence of fetal DNA in maternal blood by Lo and collaborators.18 The 
continuous remodeling of the placenta, with trophoblast cells undergoing apoptotic events, is 
responsible of the releasing of cell-free fetal DNA (cffDNA) in the blood stream of the mother. 
Because of its apoptotic origin, cffDNA is mostly short (about 200 base-pairs), it appears at 
around six weeks of pregnancy and it constitutes approximately 10% of the total cell free plasma 
DNA,19-21 thus generating an in vivo DNA mixture characterized by a large excess of maternal 
DNA (DNA microchimerism).22,23 Conventional DNA sequencing, SNPs and STRs markers 
based on PCR and capillary electrophoresis are not sensitive enough for characterizing a DNA 
contributing less than 10% to a mixed sample and sex-specific Y-STR markers cannot be used in 
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case of baby girls and to distinguish paternally related alleged fathers. Unless progress is made in 
methods for the enrichment of the fetal DNA fraction;24 one possibility for the analysis of the 
DNA microchimerism in pregnancy is the use of high-precision approaches. Digital PCR, 25 
large SNP array26 and massive parallel sequencing (MPS)27 for example, enable to detect the 
small amount of sequences from a particular locus, even when applied to a sample in which fetal 
DNA only represents a small fraction.  
Few studies evaluated the feasibility of non-invasive prenatal paternity testing by using high-
throughput SNP genotyping.28,29 In Ryan et al. 2013, an array of about 300,000 SNPs optimized 
to detect cytogenetic abnormalities most relevant to human disease is used to establish the 
genotype of the plasma DNA. The genetic information of the mother (reference sample) is used 
to identify a series of SNP alleles transmitted by the father and with a ‘Paternal Support 
algorithm’28 it is possible to estimate the probability of paternity of the alleged father. In addition 
to genotyping, this technique can be used to provide the relative quantity of alleles at each SNP 
to detect the presence or absence of fetal aneuploidies. Limitations of this approach include 
sometimes a low signal-to-noise ratio because the fetal DNA is neither enriched nor specifically 
targeted. Large-scale clinical trials are also needed to more accurately establish the specificity 
and sensitivity of the test. 
Recently, MPS has also been used to analyse cffDNA in maternal plasma.30 As above, the use of 
the maternal DNA as reference sample enables the identification of the fetal DNA and the 
maternal versus paternal DNA inheritance. Applications focused so far on the detection of 
aneuploidies, because the quantitative detection of the chromosomal dosage over an extended 
region is more feasible than single mutation analysis. For paternity testing,31-34 the method 
currently lacks informatics based analysis necessary to evaluate the accuracy with which 
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paternity is confirmed. Signal-to-noise ratio is also an issue with many informative paternally 
transmitted alleles filtered out after quality controls. 
 Both these procedures, SNP array and MPS are labor intensive and require dedicated equipment. 
Another limitation associated to the genome wide screening of the fetal DNA is that the data 
gathered provide information beyond the specific genetic question investigated and may generate 
unclear and or undesired diagnostics. 
To circumvent these problems, we developed a PCR-based method that uses allele-specific 
primers to target DNA sequences that are unique to the fetal DNA (transmitted by the father).35,36 
These sequences are biallelic deletion/insertion polymorphisms (DIP) of several nucleotides, 
mostly between three and 15. The two possible alleles are referred to as, long allele (L) and short 
allele (S). Because biallelic markers have reduced information content, we proposed the selection 
of DIP markers that are physically very close (linked) to another STR marker, for combined 
analysis. The newly generated compound markers are termed DIP-STRs (Figure 1). The 
multiallelic haplotype composed of both DIP and STR alleles is analyzed by using PCR primers 
overlapping the deleted/inserted sequence (S-DIP, L-DIP primers) on one side and downstream 
the STR region on the other side (STR primer). The sequence difference between S- and L-
specific primers of several nucleotides allows the selective (allele-specific) amplification of the 
fetal DNA contributor in the presence of large quantities (more than 1,000 fold excess) of 
maternal DNA background. In this way, it is possible to target those paternally transmitted 
alleles that are not shared with the maternal DNA. 
In this study, we determined whether the DIP-STR markers can be used to analyze cffDNA in 
maternal plasma for noninvasive prenatal diagnosis. The results from testing this new method on 
48 pregnant women with 95 samples collected at different gestational ages, show that DIP-STRs 
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can contribute to prenatal care; especially considering the potential for improvement in marker 
selection, multiplexing and quantity of maternal plasma to be used for testing. 
MATERIALS AND METHODS 
Sample collection  
Inclusion criteria for enrolled couples were singleton pregnancies with known paternity. 
Maternal blood samples (10ml) were drawn longitudinally from 48 women at 8-13 weeks (first 
trimester), 14-26 weeks (second trimester) and 27-40 weeks (third trimester) of amenorrhea. 
Samples collected during the first, second and third trimester are from 27, 28 and 40 pregnant 
women, respectively. See Table 1 for details on longitudinal sample collection. Venous blood 
samples were drawn into EDTA blood collection tubes. Plasma was separated from the blood 
cells via double centrifugation (1,600 g for 10 min, tube transfer, and centrifugation at 28,000 g 
for 10 min) within 2 hours from blood drawn. Four to five aliquots of 1 ml were stored at -20°C 
until further processing.37 
DNA samples from both parents of the developing baby were collected by buccal swab. Such 
reference samples are necessary for searching DIP-STR markers showing informative genotypes. 
Written informed consent was obtained from all participants, and genetic samples were collected 
under an institutional review board-approved research protocol. 
DNA extraction 
Cell free circulating DNA was extracted in duplicate from 2 ml of plasma by using the QIAamp 
Circulating Nucleic Acid Kit (Qiagen AG, Basel, Switzerland) according to the manufacturer’s 
protocol. Absorbed DNA was eluted with 60 µl of provided elution buffer. The synthetic DNA 
RT-SPCY-T02 (Eurogentec, Angers, France) was added to the plasma to function as positive 
control for circulating DNA extraction. According to the manufacturer’s protocol, 2 ul of a 10 
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fold diluted RT-SPCY-T02 was added to 2 ml of plasma. Reference buccal samples were 
extracted using the QIAamp DNA Mini Kit (Qiagen AG, Basel, Switzerland) according to the 
manufacturer’s protocol and eluted in 100 µl final volume. Both genomic and circulating DNA 
samples were stored at -20°C. 
Fetal DNA quantity and percent was measured in the subset of plasma samples from pregnancies 
of male fetuses. The forensic kit Investigator Quantiplex HYresTM assay (Qiagen AG, Basel, 
Switzerland) and an AB 7500 Real-time PCR system (Life Technologies Europe, Zug, 
Switzerland) was used according to the manufacturer’s protocol, data were analyzed using the 
HID Real-Time PCR Analysis Software v1.2 (Life Technologies Europe, Zug, Switzerland). 
DIP-STR genetic markers 
The DIP-STR markers genotyped for this study include 18 markers previously published35,36 and 
ten newly developed (Supplementary Table S1).  
PCR reactions for the ten new markers were performed as previously published DIP-STR 
genotyping protocols35,36 using 10 ul of plasma DNA. Primer sequences are reported in 
Supplementary Table S2. S- and L-DIP-STR specific amplifications were done in singleplex 
according to published protocols.35,36 For the ten newly developed markers primers were used at 
100 nM and 34 cycles of PCR. Annealing temperatures varied: rs71725104-STR, rs72534187-
STR, rs139592446-STR, rs36194161-STR, rs138331044-STR were amplified at 58°C, MID473-
STR, MID2538-STR, MID1739-STR, MID2824-STR at 55°C and MID73-STR at 59°C. To 
identify informative markers for plasma DNA analysis, reference DNA samples from the 
mothers and the fathers were first genotyped for 28 DIP markers using four multiplex reactions 
as described in Supplementary Table S3. For all markers PCR thermal cycling conditions were: 
5 min at 95°C, 1 min at 94°C, 1 min at annealing temperature specific to the markers set to be 
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genotyped, 1 min at 72°C for a number of PCR cycles that also varied across multiplex and a 
final extension of 30 min at 72°C.  
PCR fragments were separated by capillary electrophoresis after adding 1 μl PCR amplicon to 
8.5 μl deionized formamide HI-DI (Life Technologies Europe, Zug, Switzerland) and to 0.5 μl 
600 LIZ size standard (Life Technologies Europe, Zug, Switzerland). Capillary electrophoresis 
was performed using an ABI PRISM 3130xl Genetic Analyzer (Life Technologies Europe, Zug, 
Switzerland) according to the manufacturer's instruction and analyzed using the GeneMapper® 
ID v3.2.1 software (Life Technologies Europe, Zug, Switzerland), with a minimum peak height 
threshold of 50 Relative Fluorescence Unit (RFU). The commercial DNA CEPH 1347-02 (Life 
Technologies Europe, Zug, Switzerland) was used as positive control of amplification and 
internal standard for allele designations. For standard PCR reactions (28-30 cycles) 0.5 ng of 
CEPH 1347-02 DNA was used, for all PCR reactions with increased number of cycles (34-36) 
0.0125 ng of CEPH 1347-02 DNA was used.   
RESULTS 
Type of informative markers 
As described above, the target analysis of circulating fetal DNA is based on allele-specific 
amplifications of those haplotypes showing DIP differences between the mother and the 
paternally transmitted DNA.  To do so, primers are selected based on the DIP genotype of the 
mother. Markers informative for the genotypes of the fetus are DIP homozygous in the mother 
(SS or LL) and should be analyzed using primers specific to the opposite DIP allele (L- and S-
primers, respectively). The fetal allele is then targeted if a DIP allele, different from the mother 
is transmitted by the father. Considering all possible genotype assortments, three types of 
informative  markers exist (Figure 1): markers of type A, the father is homozygous for the DIP 
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allele that is not shared with the mother, in this case the paternal haplotype can be targeted in 
maternal plasma regardless which one is transmitted to the fetus; markers of type B, the father is 
heterozygous at the DIP locus, in this case the paternal DNA can be targeted in maternal plasma 
if the transmitted haplotype carries the DIP allele not shared with the mother; finally, markers of 
type C, the father is homozygous at the DIP locus for the same allele of the mother, in this case 
no paternal haplotype can be targeted in maternal plasma. 
In Supplementary Table S4 is reported the number of each type of informative marker per 
family. Most of the parental genotypes  we studied showed two and three markers of type A, 
about 8 of type B and 6 of type C. Interestingly, the few parents (ID 6,15 and 18) showed no 
markers of type A had between five and ten choices of type B markers that allowed in practice 
the detection of the paternally transmitted DNA. 
Detection of cffDNA by selected DIP-STRs 
To test if DIP-STR markers could be used to detect fetal DNA across families and time points, 
each plasma sample was genotyped for at least one marker of type A. When many informative 
markers were available, the shortest was selected for this pilot study. As described above, 
families 6, 15 and 18 showed no marker of type A, therefore markers informative of the 
paternally transmitted alleles were identified by testing several markers of type B.  
To further check for PCR specificity, we first genotyped plasma samples where the fathers were 
heterozygous for the STR composing the DIP-STR haplotype. The results of few representative 
samples are illustrated in Figure 2. Samples relative to family 2 never worked because of the 
insufficient blood collection (2.5 ml instead of 10 ml) (Table 2). Seven plasma samples gave 
positive results after modification of the PCR protocol to include 36 cycles and eight plasma 
samples never worked with the selected DIP-STRs. This represent 6.9 % of false negative results 
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considering eight fetal DNA amplifications out of 116 PCR tests performed. The markers 
associated to these weak and negative results are all characterized by low PCR efficiency as 
previously reported,35,36 these are L-rs35032587-STR, S- and L-rs71070706-STR and L-
rs111478323-STR and L-rs112604544-STR. To report on the signal-to-noise ratio of the assay, 
in Supplementary Figure S1 are shown the  electropherograms results of cffDNA detection in 
maternal blood for the samples collected during the first and second trimester that showed low 
RFU values (<100 RFU). Overall, some markers appeared more sensitive than others, but the 
quantity of the PCR product obtained did not correlate with the time in pregnancy. 
Detection of cffDNA using long DIP-STRs 
The use of long DIP-STR markers on a reduced number of samples also showed positive results. 
Alleles of 300, 305, 335, 337, 348, 360 and 386 base-pairs were successfully amplified in nine 
different families (ID 30and 32, 42 and 47, 48, 8, 13, 31) using different markers and samples 
collected at both early and late pregnancy. The results of few representative samples are 
illustrated in (Figure 3a). These families were selected solely based on the occurrence of long 
DIP-STR informative markers of type A, without other specific selecting criteria.  
Detection of cffDNA during early pregnancy 
The blood samples collected during the first trimester of pregnancy were mostly drawn between 
12 and 13 weeks of gestational age. One sample (ID 49) was collected at 10 weeks and 2 days of 
amenorrhea and could be used to test the DIP-STR based fetal DNA detection in early 
pregnancy.  The only marker tested with this sample, S-MID1739-STR gave a positive result 
(Figure 3b).  
Correlation between fetal DNA quantity and DIP-STR results 
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The subset of plasma samples collected from women bearing male fetuses during the first and 
second trimester were selected to quantify the fetal DNA fraction and to investigate a possible 
correlation to DIP-STR results. The data reported in Supplementary Table S5 indicate that 
positive results are obtained using as low as 0.029 ng of fetal DNA representing 3.5 % of plasma 
DNA. The strength of the signal (RFUs) varies depending on the sensitivity of the markers used 
as previously reported. Note that samples showing false negative results (NR) do not show the 
lowest fetal DNA quantity or fraction.  
DIP-STR markers not used for cffDNA detection 
Because of the specific occurrence of informative markers in these families, not all available 
DIP-STRs have been used for cffDNA detection. Markers MID1013–D5S490, MID1950 -
D20S473, rs60194384-D15S1514, rs72534187-STR, rs138331044-STR, MID73-STR were not 
tested in this study. Markers MID1107-D5S1980, rs35708668-D5S2045 and rs10564579-
D3S1282 were sometimes among the informative markers but they were not selected because of 
their long size (600-700 bp). Finally, some markers were tested for only one DIP-STR allele 
such as L-rs67842608-D5S468, S-rs66679498-D2S342, L-rs10564579-D3S1282, L-rs72406828-
STR, L-rs145423446-STR, L-rs139592446-STR, S-rs36194161-STR, S-MID1739-STR.  
DISCUSSION 
Our results show that cell-free fetal DNA in maternal plasma can be detected by applying novel 
DIP-STR genetic markers, that we originally developed for the analysis of DNA mixtures 
encountered in forensic trace analysis. The results showed positive detection of fetal DNA, 
regardless of sex type, in the plasma of 48 women whose blood was collected during the first, 
second and third trimester of pregnancy. With few exceptions, all tested markers could detect the 
fetal DNA, including longer ones targeting DNA fragments up to 386 base-pairs. Positive results 
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were also obtained with one sample collected during early pregnancy at 10 weeks of gestational 
age. Yet, more samples collected between six and 10 weeks are necessary to validate the method 
for early noninvasive diagnostic purposes.  
Overall, we observed a 6.9 % (8/116 PCR assays) of false negative results. The plasma samples 
(N=31) in which the fetal DNA fraction could be quantified by Y chromosome markers, showed 
values from 3.5 % to 19.2 % and no correlation between low fetal DNA quantity or fraction and 
DIP-STR results. No issue of fetal DNA extraction efficiency was reported by the internal 
control of extraction. Moreover, families with false negative results showed low marker 
performance longitudinally during the first, second and third trimester (see Table 2 for ID 17, 19, 
21, 35, 37 and 42) and often with the same few markers, such as rs717070706-STR. Based on 
the observations, we interpreted the negative PCR results as mainly due to few low sensitive 
markers. On the other hand, no false positive result were generated by the large excess of 
maternal DNA, in agreement with our marker validation results that assessed allele-specificity up 
to a mixture ratio of 1:1000. These results confirm the sensitivity and specificity of the DIP-
STRs for targeting the minor DNA component of plasma DNA, even when fetal DNA molecules 
are of reduced numbers, such as in early pregnancy or because of the use of long markers.  
These data provide the basis for the development of a non-invasive prenatal paternity test, rapid 
and cost-effective, easy to implement (one or two PCR multiplex) in any forensic or medical 
genetics laboratory. Such molecular approach would offer several advantages with respect to 
currently developing methods: i) a targeted approach that guarantees a careful separation 
between paternity tests and disease diagnoses (aneuploidies and mutation discoveries), ii) a 
molecular system that is shared with other forensic and medical applications where the risk for 
false positive and negative result is carefully measured and the appropriate statistical framework 
14 
 
is available (Bayesian approach). Finally, iii) the choice of different type of informative markers 
(type A, B and C) provides a useful flexibility in testing different scenarios including one, 
multiple or unknown alleged fathers that can be associated to various degree of statistical power. 
As explained in the introduction and previous publications, the number of markers capable of 
targeting the fetal DNA based on allele difference between maternal DNA and paternally 
transmitted alleles, is expected to vary across cases. As observed here with 49 families; 28 DIP-
STR generate on average three markers of type A, where the parents are opposite homozygous 
for the DIP allele and at least one paternal allele is detected; seven marker of type B, that means 
one paternal allele could be detected if transmitted and seven markers of type C, that is mainly 
used for exclusion since negative results are expected. To bring our method closer to medical 
practice, we plan to, first develop the statistical framework necessary for the analysis of DIP-
STR genotypes in the context of paternity testing. Bayesian models will be used as they are 
generally accepted in forensic science to evaluate the strength of DNA evidence. Second, based 
on the model above, we will study how likelihood ratios values vary depending on the number 
and types of informative markers considering a set of simulated families. 
Our results also showed that the sensitivity of the technique may vary across DIP-STRs and we 
recorded four DIP-STRs (out of 19 markers tested on clinical samples) not sensitive enough for a 
positive/robust amplification of circulating fetal DNA in the conditions tested. Therefore, a 
suitably designed multiplex for amplification is needed including careful measurements of 
markers sensitivity and specificity, especially to assist the interpretation of results from markers 
of type B and C. Ideally, in case of negative results one should have a universal fetal DNA 
marker to demonstrate the presence of amplifiable fetal DNA. Moreover, we plan to explore the 
use of a larger (> 2ml) volume of plasma for DNA extractions. Note that the drawing of more 
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blood (> 10 ml) is possible without adducing important discomfort to the patient.  Moreover, 
Streck BCT blood collection tubes could be used to facilitate the sample collection within a 
clinical environment. These tubes reduce the need for immediate plasma preparation by 
stabilizing nucleated blood cells at temperatures between 6°C to 37°C, for several days. 
Although we achieve high levels of allele-specificity with the DIP-STR genotyping approach, 
(markers are specific up to 1:1000 DNA ratio) and we didn’t observe issue of maternal DNA 
amplification, it is still possible that reducing the quantity of background maternal DNA the 
performance of less sensitive markers improves. This strategy could be the solution for early 
pregnancy tests, if studies on a larger cohort indicates that marker sensitivity is limiting. 
However, it should be noted that several reports indicated that the quantity of cffDNA varies 
little during pregnancy.  
Finally, of interest is an initial comparison of this method to published noninvasive prenatal 
paternity tests even at this early stage of development (no calculation of paternity index for the 
described cases) where ‘inconclusive results’ are due to false positive and false negative markers. 
Ou’s group published several articles32-34 where they use SNPs panels for the analysis of 
paternally inherited alleles in maternal plasma using MPS techniques. These studies show that, 
although results change with the specific technology used (sequencing technology, library 
preparation, coverage, number of SNPs), a panel of 720 SNPs has 11 % of poorly performing 
markers that need to be eliminated and a low signal-to-noise ratio that requires considering 
samples with a minimum fetal DNA fraction of  2 %. When this threshold is used and suboptimal 
SNPs are eliminated, 10 % to 50 % of paternally transmitted alleles from the subset of 
informative SNPs (about 40 % on average) are filtered out, and 0 % to 11 % when samples are 
collected during the second trimester. Events of allele drop-in are also observed by using MPS 
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with three extra alleles in 20 families reported. With respect to studies using SNP arrays,28 the 
authors declare that each individual SNP measurement is noisy but technical false positive and 
false negative rates are not reported. Conversely, the 384 SNP method by allele-specific PCRs of 
Guo et al. 201229 indicated 13.3 % of false positive and 2.7 % of false negative rates. In our 
study the false negative rate is 6.9 % including poorly performing DIP-STRs (4 markers) that 
were not eliminated and false positive results were not observed. Indeed, interrogating a large 
number of markers, as for MPS or SNP arrays, offers the advantage of reducing the issue of false 
positive and false negative results, however an appropriate signal quality control and statistical 
framework for results interpretation needs to be developed. 
Therefore, of interest is the possibility of integrating novel large-scale technologies although 
keeping a targeted approach. The use of high throughput sequencing, instead of capillary 
electrophoresis, for fragment analysis will offer an improved capacity in the number of markers 
analyzed and more flexibility in primer design. The requirement of this sophisticated technology 
will be elucidated after measuring the statistical power of this initial set of DIP-STR markers on 
data from a large number of families simulated for paternity tests.  
In summary, we show that the use of DIP-STR markers for targeting the analysis of fetal DNA 
circulating in the blood of a pregnant woman is possible and can be used for noninvasive 
prenatal paternity testing. Further study is warrant to determine the number of informative 
markers necessary for obtaining conclusive results on paternity across parental genotypes. 
Conversely, for diagnostic purposes entirely new DIP-STRs should probably be developed 
depending on the genomic region of interest. In this regard, we previously estimated that several 
thousands of DIP-STRs exist35 in the genome and that their availability should not limit the 
adaptation of this technique to specific needs.  
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 FIGURES LEGENDS 
Figure 1 Types of informative DIP-STRs. Markers of type A, the mother and the father are 
homozygous for different DIP alleles. With this marker, the paternally transmitted DIP-STR 
haplotype can be targeted in maternal plasma using allele-specific primers. Markers of type B, 
the mother is DIP homozygous and the father is DIP heterozygous. With this marker, the 
paternally transmitted DIP-STR haplotype can be targeted in maternal plasma only if the 
transmitted haplotype carries a DIP allele not shared with the mother. Markers of type C, the 
mother and the father are homozygous for the same DIP allele. With this marker, no paternally 
transmitted DIP-STR haplotype should be detected in maternal plasma. 
Figure 2 Examples of fetal DNA detection in maternal plasma with DIP-STR markers.  
Electropherogram results of the positive detection of the paternally transmitted alleles in 
maternal blood collected during the first and second or third trimester. The detected allele can be 
compared to the paternal genotype indicated below. The STR heterozygosity of the father allows 
to confirm the target amplification of the paternal halotype transmitted to the fetus. Primers are 
selected to be specific to the paternally transmitted alleles of the cffDNA, therefore as expected 
no PCR product is detected when using the reference DNA of the mother (a): family 51, marker 
rs36194161-STR. (b): family 31, marker MID473-STR. (c): family 27, marker MID473-STR. 
Figure 3 Examples of fetal DNA detection in maternal plasma with long DIP-STR markers 
and one example of fetal DNA detection at ten weeks of pregnancy.  
Electropherogram results of the positive detection of the paternally transmitted alleles in 
maternal blood using long DIP-STR markers. (a): Above, family 13, marker L-rs11277790-
D10S530. Below, family 31, marker L-rs67842608-D5S468. (b): Electropherogram results 
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showing one case of positive detection of the paternally transmitted allele in maternal plasma 
collected at ten weeks of pregnancy. Family 49, marker S-MID1739-STR. 
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Table 1 Plasma samples and relative gestational age of the fetus 
 
Mother 
ID 
 
First trimester 
 
Second trimester 
 
Third trimester 
1     24.3   37.0  
2     15.0 26.4  36.0  
3        34.1 38.1 
4        28.5  
6        27.6 39.0 
7     16.5   30.4 35.5 
8  12.5      27.6 39.4 
9     16.2   36.1  
10  12.0   25.1     
11        32.1 37.4 
12  13.2   22.2   35.5  
13     23.2   36.2  
14     15.5   35.6  
15  12.2   22.1   36.6  
16        34.0  
17  12.2   21.1   37.1  
18  13.5      32.1  
19  13.0   24.2   38.3  
20  12.4        
21  12.3   25.4   39.0  
22  12.4      33.5  
23  12.6      37.5  
24     16.0 26.3    
25     15.6 24.5  36.5  
26     16.1   28.0 37.2 
27  13.0   22.6     
28  13.3      36.3  
29  12.3      29.5 36.6 
30  13.0   23.0     
31  12.3   25.3   36.3  
32     16.5   29.5 37.3 
33  12.6      34.2  
34     15.2   28.0 36.6 
35     16.0   32.3  
36  13.0   25.1     
37     16.3   30.5 35.6 
38     16.0     
41     20.5   35.5  
42  11.6      27.3  
43  12.0        
44  12.5   24.4   37.5  
45  12.2   25.1   36.2  
46  12.6      29.3 39.5 
47  12.4      33.1 39.2 
48  13.0      37.0  
49  10.2      30.0 36.0 
50     16.5 26.3  35.5  
51  12.4         34.6   
Samples 5, 39 and 40 were not included because of study participation withdrawal. 
Gestational age is indicated in weeks.days. 
 
Table
Table 2 Marker size and peak height in Relative Fluorescence Unit (RFU) of fetal DNA specific amplifications 
from maternal plasma 
Mother 
ID 
 
Marker 
 Size 
(bp) 
 First trimester 
(RFU) 
 Second trimester  
(RFU) 
 Third trimester 
(RFU) 
1  rs35032587-STR-L  259     53a   50a  
2  rs35032587-STR-S  247-251     NR NR  NR  
3  MID1739-STR-S  210        2766 600 
4  rs139592446-STR-L  159        8780  
6  rs34212659-STR-S  191        297 99 
7  rs142543564-STR-L  234     54a   64a NT 
8  MID2824-STR-S 
rs11277790-D10S530-S 
 198 
348 
 50 
70 
     4881 
NT 
4865 
NT 
9  MID2824-STR-S  198     8590   420  
10  MID2824-STR-S  198  58   1288     
11  rs142543564-STR-S  210        412 52 
12  rs71725104-STR-S  219  546   172   1051  
13  rs145423446-STR-L 
rs11277790-D10S530-L 
 244 
360 
    1718 
210 
  5031  
14  rs36194161-STR-S  170     51   121  
15  rs34212659-STR-S  191  4109   2160   1175  
16  rs146332920-STR-L  179        651  
17  rs71070706-STR-S  241  NR   NR   60  
18  rs146332920-STR-S  192  688      923  
19  rs111478323-STR-L  240  93a   NR   192  
20  MID2824-STR-S  198  57        
21  rs71070706-STR-L  241  NR   NR   211  
22  MID473-STR-S  195  86      1871  
23  MID1739-STR-S  210  1898      5646  
24  rs72406828-STR-L  200     584 484    
25  rs139592446-STR-L 
MID1013-D5S490-L 
 159 
337 
    162 
52 
7000 
210 
 7000 
NT 
 
26  rs34212659-STR-S  191     1070   1763 4371 
27  MID473-STR-S  195  1042   993     
28  MID2824-STR-S  198  59      1017  
29  MID473-STR-L  211  1439      825 1867 
30  MID2538-STR-S  300  7000   6849     
31  MID473-STR-S 
rs67842608-D5S468-L 
 195 
386 
 8169 
1000 
  6700 
NT 
  8077 
NT 
 
32  MID2538-STR-S  300     118   431 105 
33  rs111478323-STR-L  240  50      102  
34  MID2824a-STR-S  198     567   9175 8340 
35  rs71070706-STR-L  249     NR   67  
36  MID473-STR-L  215  8157   8070     
37  rs112604544-STR-L  160     NR   57a 31a 
38  rs71725104-STR-L  227     87     
41  MID473-STR-L  215     1200   896  
42  MID2538-STR-L  305  NR      164  
43  rs111478323-STR-S  240  52        
44  MID2824-STR-L  214  55   360   673  
45  MID1739-STR-S  210  376   550   6024  
46  MID1739-STR-S  210  247      130 2715 
47  MID2538-STR-L 
rs36194161-STR-S 
rs34212659-STR-L 
 305 
161 
187 
 1265 
54  
68 
     595 
996 
551 
NT 
48  rs66679498-D2S342-S  335  128      336  
49  MID1739-STR-S  201  359      146 398 
50  rs72406828-STR-L  210     1606 1300  392  
51  rs36194161-STR-S  158  252        884   
a 36 cycles of PCR. 
NT Sample not tested. 
NR Sample showing negative results. 
Table
Supplementary Table S1 DIP-STR marker list 
 
DIP-STR Chr. DIP S/L sequence STR repeat 
DIP-STR sizeb 
(bases) 
Reference 
MID1013-D5S490 5q23.2 -/CCAG GT 299-345 Castella et al. 2013 
MID1950 -D20S473 20p13 -/ATT TTA 205-238 Castella et al. 2013 
MID1107-D5S1980 5p15.33 -/AACA CA 650-680 Castella et al. 2013 
rs11277790-D10S530 10q25.1 -/TCCAACT GT 340-371 Castella et al. 2013 
rs60194384-D15S1514 15q26.2 -/TCTTAA TATC 283-325 Castella et al. 2013 
rs67842608-D5S468 5q11.2 -/TGGTTTAA GT 379-395 Castella et al. 2013 
rs66679498-D2S342 2q32.3 -/CCAACTTTCTCCTAC CA 331-359 Castella et al. 2013 
rs10564579-D3S1282 3p24.1 -/GTCATA CA 714-728 Castella et al. 2013 
rs35708668-D5S2045 5q34 -/TACTATGTAC CA 621-649 Castella et al. 2013 
rs35032587-STR 15q26.1 -/TATT AGAT 239-271 Oldoni et al. 2015 
rs142543564-STR 2q34 -/TACT ATAA 210-238 Oldoni et al. 2015 
rs34212659-STR 7p14.1 -/AGG TGAA 182-199 Oldoni et al. 2015 
rs112604544-STR 1q25.3 -/TTTAA TTCC 134-204 Oldoni et al. 2015 
rs111478323-STR 2p25.3 -/GAGA TTTA 229-265 Oldoni et al. 2015 
rs146332920-STR 9q31.3 -/AGG TAAA 179-207 Oldoni et al. 2015 
rs71070706-STR 1p12 -/TGT AAAG 212-264 Oldoni et al. 2015 
rs72406828-STR 4q21.3 -/ATTG AATTT 178-250 Oldoni et al. 2015 
rs145423446-STR 16p13.2 -/AGTC GATA 230-256 Oldoni et al. 2015 
rs71725104-STR 13q31.3 -/ATAG AAAT  211-235  
rs72534187-STR 5p13.1  -/ACAGGCC ATAG  208-236   
rs139592446-STR 2q24.2  -/ACTTAGTC CATC  154-174   
rs36194161-STR 2q32.1  -/CTC TTTA 138-178   
rs138331044-STR 1p12  -/CATATGC AGAT 266-302   
MID473a-STR 6q16.1 -/TTACATTT AGGA  179-227   
MID2538a-STR 15q25.3  -/TGTT AC 299-311   
MID1739a-STR 6q14.1 -/GTCAGG TG 201-226  
MID2824a-STR 11p13  -/AGGACT AAAC  197-222   
MID73a-STR   22q12.3  -/GAA CCACT  362-442   
aMarker name is from the Marshfield database and corresponds to rs140762, rs3054057, rs397772033, rs11278940, rs16365, 
respectively. 
bDIP-STR sizes are based on the genotypes of the HGDP-CEPH global reference population (1064 individuals), except for 
markers MID1107-D5S1980, rs67842608-D5S468, rs10564579-D3S1282, rs35708668-D5S2045 that were genotyped in a 
reduced sample of 103 Swiss individuals, as described in Castella et al. 2013. 
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Supplementary Table S2 DIP-STR primer sequences (5’ - 3’) for the subset of unpublished markers 
Marker DIP primer 
 
STR primer S-DIP allele-specific primer 
L-DIP allele-specific primer 
DIP-STR reverse primer 
    
rs71725104-STR *TTTTTGCCACAAAACTAAATT *GTGTGGTGGTAGCTGGGACT CCTTTCCTTCTATTCTTGCTTTAT.TTT 
 GCAGCTCCTGCAAAAATTTC TTTTGTGGCAAAAACTTTGG CCTTTCCTTCTATTCTTGCTTTATCTA 
   *GTGTGGTGGTAGCTGGGACT 
    
rs72534187-STR *GCTCATGCAATTGATCAAACC *GGTATGCAATCTATCCTGATGTGA TCTCTGGTTCTCTAGCTTGTAGAT.TAC 
 GCTTTGGGCTTGATACAGAAA TGCATGAGCCAATTTATCTGA CTCTAGCTTGTAGATGGCCTGTTA 
   *AGGCCAAAATTGACATTATAGTTTA 
    
rs139592446-STR *ACTGGGAAAACTATGAGAAACAAA *GATTTAGGAGGGGATGTGGT CCATTTTGCCCCACTAGT.TC 
 CCTTCCTTTTATCTTCTATCACACA TTTCCCAGTGTCTGCTCAA TGCCCCACTAGTGACTAAGTTC 
   *TAGCCTTCTGCCCAAACATC 
    
rs36194161-STR *CCAAGATTGTGCCACTGC *AAAACATACCCAAGACCTGGTG AAATATTACTAGTTGTATTAGTCTGTT.ACG 
 TCACCAGGTCTTGGGTATGTT TTTAAACCTCTTTCCTGCTTGC TATTACTAGTTGTATTAGTCTGTTCTCAC 
   *TGCAGTGAGCAGGGTGAC 
    
rs138331044-STR *ACAATCGCTGCTCACTGAAG *AGCACATAGCAGGCACTAGC ATTAGCTGGGCTTAGTG.CCTGT 
 GCCGAAGCAGGTGTATTTCT GCGATTGTGCCACTACACAG TAGCTGGGCTTAGTGGCATATG 
   *GCACTAGCTGTTAGTTCCTTTTCTG 
    
MID473-STR *AAATGTTAAGCCTCCCCTGTC *CCTTGTCTTGGTTGTTGCTG TGGGCTTTCTA.TTACATTTTTAGC 
 CCACTGACAGCAACAACCAA TGCAGGCAGATTTTAAAGGAA TGGGCTTTCTATTACATTTTTACAT 
   *TGCAGGCAGATTTTAAAGGAA 
    
MID2538-STR *AACAATCTTGGCACCCATTT *TCATTACCTTCTCTGCATTGGA GTTCAAAATCACAATCACTCA.TTT 
 GCTCGCAAAGTAGGCAAGTT GTGCCAAGATTGTTGGTGTG TCAAAATCACAATCACTCAAACA 
   *TGGAATCACTCATTACCTTCTCTG 
    
MID1739-STR *GCACACATGTAGCAATGGTTT *GGGAATTCATCCTCATTTTCC CGTAGATATGTGTCTCTA.CCTGACTG 
 GCTCGCTCTTAATTGCATCC AACCATTGCTACATGTGTGCTT ATATGTGTCTCTACCTGACCCTGAC 
   *GGGAATTCATCCTCATTTTCC 
    
MID2824-STR *TGTTCCACTTCTGCCATGTG *ACTTGGGAGGCTGAGACAGA TCCAAGATGAGCACTG.GGC 
 TCTAGTGGGGGTTTGCAGAG CACATGGCAGAAGTGGAACA CCTCCAAGATGAGCACTGAGTC 
   *CCAGCCTGGCAACAGAGTA 
    
MID73-STR *TGTGTTTCTAAGGAGCGCTGT *CCATTCTCTCCTTCCTTCTCC CATACTCAGAACTGCCTT.GAAAAG 
 CACAGTGAGGAGAAGGAAGGA CCTGGTGCCAGAGCACAT CATACTCAGAACTGCCTTGAAGAA 
   *GCACATGGCTCTTTAATACACTG 
*Fluorescent labeled primers. In the last column dots indicate the insertion/deletion point and underlined is the inserted sequence. Primers for markers previously published were 
not changed. 
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Supplementary Table S3 DIP-multiplex reactions 
 
Multiplex group Marker Primers DIP (nM) 
1-annealing temperature 52°C, 28 cycles MID1013-D5S490 100 
 MID1950 -D20S473 200 
 MID1107-D5S1980 100 
 rs11277790-D10S530 100 
 rs60194384-D15S1514 200 
 rs67842608-D5S468 100 
 rs66679498-D2S342 200 
 rs10564579-D3S1282 200 
 rs35708668-D5S2045 100 
   
2-annealing temperature 55°C, 34 cycles rs35032587-STR 200 
 rs142543564-STR 100 
 rs34212659-STR 100 
 rs112604544-STR 100 
 rs111478323-STR 50 
 rs146332920-STR 50 
 rs71070706-STR 50 
 rs72406828-STR 150 
 rs145423446-STR 100 
   
3-annealing temperature 55°C, 34 cycles rs71725104-STR 150 
 rs72534187-STR 75 
 rs139592446-STR 150 
 rs36194161-STR 150 
 rs138331044-STR 120 
   
4-annealing temperature 55°C, 30 cycles MID473-STR 100 
 MID2538-STR 100 
 MID1739-STR 100 
 MID2824-STR 400 
 MID73-STR   400 
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Supplementary Table S4 Number of informative markers 
 
Mother ID  N informative markers 
   type A  type B  type C 
1  2  1  11 
2  1  3  9 
3  4  8  3 
4  6  8  6 
6  0  10  12 
7  3  8  10 
8  6  6  13 
9  5  6  7 
10  9  6  4 
11  2  9  5 
12  5  4  3 
13  3  3  5 
14  4  9  6 
15  0  5  6 
16  7  5  6 
17  1  10  9 
18  0  10  6 
19  3  10  5 
20  4  7  3 
21  2  2  8 
22  2  9  4 
23  5  8  6 
24  2  7  11 
25  3  12  5 
26  3  5  7 
27  3  8  10 
28  3  9  9 
29  3  7  7 
30  2  8  6 
31  2  9  5 
32  4  3  6 
33  2  8  7 
34  2  6  10 
35  1  12  8 
36  2  4  9 
37  3  8  9 
38  3  8  6 
41  2  8  9 
42  2  5  9 
43  3  11  6 
44  1  6  12 
45  2  9  6 
46  3  9  6 
47  2  6  9 
48  3  8  6 
49  4  11  7 
50  4  8  9 
51   4   7   6 
See Figure 1 for description of informative markers. 
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Supplementary Table S5 Quantity and percent of fetal DNA in the subset of pregnant women bearing male fetuses 
with samples collected during the 1st and 2nd trimester 
Mother ID Trimester 
Quantity of fetal DNA  
amplified (ng) 
Percent of fetal DNA  
in plasma cfDNA 
Results of Table 2 
(RFU) 
7 1st 0.035 4.4 54 
8 1st 0.056 5.5 50 
9 1st 0.035 9.4 8590 
12 1st 0.074 8.0 546 
12 2nd 0.140 15.7 172 
14 1st 0.066 6.3 51 
19 1st 0.084 15.1 93 
19 2nd 0.107 15.2 NR 
21 1st 0.058 14.4 NR 
21 2nd 0.157 17.2 NR 
22 1st 0.089 6.4 86 
24 1st 0.067 9.7 584 
24 2nd 0.044 10.3 484 
26 1st 0.841 10.3 1070 
30 1st 0.117 7.6 7000 
30 2nd 0.080 6.8 6849 
32 1st 0.072 6.3 118 
33 1st 0.072 6.1 50 
34 1st 0.080 9.2 567 
35 1st 0.072 8.7 NR 
36 1st 0.051 4.6 8157 
36 2nd 0.063 10.0 8070 
38 1st 0.034 7.1 87 
41 1st 0.029 3.5 1200 
42 1st 0.024 5.7 NR 
43 1st 0.025 10.5 52 
47 1st 0.036 6.6 1265 
48 1st 0.035 10.1 128 
49 1st 0.029 7.8 359 
50 1st 0.071 11.8 1606 
50   2nd 0.112 19.2 1300 
NR Sample showing negative results. 
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Electropherograms results of the subset of cffDNA detections that showed low RFU 
values (<100 RFU) during the first and second trimester. For sample 47, rs3619461-
STR-S rs34212659-STR-L markers were amplified in multiplex.
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